Redx Pharma plc First RXC006 data for treatment of fibrosis
30 November 2018 - 6:01PM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
30 November 2018
REDX PHARMA PLC
("Redx" or "the Company")
First RXC006 data suggests it has great potential for the
treatment of fibrosis
First-in-man studies earmarked for 2020
Alderley Park, 30 November 2018 Redx (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that it presented pre-clinical data for its newly
nominated development candidate RXC006 at the Advances in Fibrosis
Drug Discovery Conference in Cambridge, USA on 29 November 2018.
RXC006, a novel inhibitor of the porcupine enzyme, will be
developed as an orally administered, first-in-class treatment for
the orphan disease, idiopathic pulmonary fibrosis (IPF). IPF is a
severe and life-threatening chronic lung condition with very poor
prognosis and limited treatment options. The company expects to
commence first-in-man studies with RXC006 during 2020.
In the first public disclosure of data on RXC006, Dr Peter
Bunyard, Head of Fibrosis at Redx, presented results from
preclinical studies in a plenary session as well as a poster which
showed that RXC006 was highly effective at suppressing the Wnt
pathway (porcupine sits on the Wnt pathway) and that RXC006 was
able to suppress lung fibrosis, in vivo. Suppression of fibrosis
has also been shown in animal models of both liver and kidney
fibrosis.
More specifically, it was shown that RXC006 was able to suppress
the release of Wnt-5a (another protein on the Wnt pathway) from
human lung fibroblasts at nanomolar concentrations and reduce
fibroblast activation. In two separate mouse models of disease,
RXC006 strongly reduced collagen deposition and significantly
impacted Ashcroft scores (a validated scale for estimating the
severity of pulmonary fibrosis), when dosed therapeutically.
Dr Jörg Distler, Professor of Internal Medicine, University of
Erlangen-Nuremberg, Germany and a key opinion leader in the
development of novel anti-fibrotic therapies, commented: "Wnt
pathway inhibition presents a novel and exciting opportunity to
treat fibrotic diseases, I truly support the idea of targeting the
porcupine enzyme."
Dr Richard Armer, Chief Scientific Officer, Redx Pharma plc
added: "The data suggests that RXC006 has great potential to treat
fibrosis in human patients. Redx are progressing RXC006 towards the
clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan
to initiate first in man clinical trials during 2020."
There is strong scientific evidence that the Wnt pathway is
critically involved in the scarring process (fibrosis) in the lung
that is the hallmark of IPF.(1) Over time, this leads to the lungs
being unable to function effectively, ultimately resulting in
suffocation and death. RXC006 represents a novel approach to treat
this debilitating and progressive disease through targeting
porcupine, a component enzyme of the Wnt pathway. Porcupine
inhibition suppresses the release of all Wnt ligands and therefore
should eliminate one of the major drivers of fibrosis in IPF. The
median survival from IPF diagnosis is 3 years and the annual
incidence is between 6.8-16.3/100,000 population in the U.S.(2)
The poster presentation is available via this link here: RXC006
AFDD Meeting Poster.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Richard Armer, Chief Scientific Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded
on AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
About IPF
IPF is a life threatening fibrotic lung condition with diagnosed
prevalence projected to increase from 119,000 (2015) to 138,000
(2025). Current treatment options are OFEV(R)(nintedanib) and
Esbriet(R) (pirfenidone); both slow progression of disease by
approximately 50%. Product sales in IPF are projected to increase
from US$ 0.9b (2015) to US$3.2b (2025). (2)
About RXC006
Redx has invested into research to target the Wnt /ß-Catenin
signalling pathway by inhibition of the upstream porcupine enzyme
and has built considerable knowledge and expertise in this
scientific area. Our most advanced porcupine inhibitor, RXC004, is
currently being investigated clinically for the treatment of a
range of cancers. RXC006 is a potent porcupine inhibitor protected
by discrete Intellectual Property and has a predicted human PK
profile which will allow flexibility in dosing regimens to balance
efficacy with potential side effects. RXC006 is the first porcupine
inhibitor aimed at treating IPF.
References
1. Newman DR, Sills WS, Hanrahan K, Ziegler A, Tidd KM, Cook E, Sannes PL.
Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its
Control by TGF-<BETA> and WNT7B in Human Lung Fibroblasts. J
Histochem Cytochem. 2016 Feb;64(2):99-111.
2. Global Data Opportunity Analyser 2015, based on 7 major markets
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEALFNALPPFFF
(END) Dow Jones Newswires
November 30, 2018 02:01 ET (07:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024